
  
    
      
        Background_NNP
        Amprenavir_NNP (_( APV_NNP )_) is_VBZ a_DT potent_JJ protease_NN inhibitor_NN (_( PI_NNP )_)
        that_WDT is_VBZ used_VBN in_IN combination_NN with_IN other_JJ antiretroviral_NN drugs_NNS
        for_IN the_DT treatment_NN of_IN antiretroviral-naïve_JJ and_CC -_: experienced_VBN
        adults_NNS and_CC children_NNS with_IN HIV_NNP infection_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._. APV_NNP
        offers_VBZ the_DT convenience_NN of_IN twice-daily_JJ (_( BID_NNP )_) administration_NN
        with_IN no_DT food_NN or_CC fluid_JJ restrictions_NNS [_NN 6_CD 7_CD ]_NN ._. Preclinical_NNP
        and_CC clinical_JJ data_NNS suggest_VBP that_IN APV_NNP has_VBZ a_DT lower_JJR potential_JJ to_TO
        cause_VB lipodystrophy_NN and_CC metabolic_JJ abnormalities_NNS than_IN other_JJ
        currently_RB available_JJ PIs_NNP [_NN 8_CD 9_CD 10_CD ]_NN ._. APV_NNP has_VBZ a_DT distinct_JJ
        resistance_NN profile_NN that_WDT permits_VBZ it_PRP to_TO be_VB considered_VBN as_IN a_DT
        treatment_NN option_NN for_IN either_DT PI-naïve_NNP or_CC PI-experienced_NNP
        patients_NNS [_NN 11_CD ]_NN ._. In_IN a_DT 64_CD -_: week_NN trial_NN in_IN treatment-naïve_JJ
        patients_NNS (_( NZTA_NNP 4002_CD ;_: n_NN =_SYM 302_CD )_) ,_, APV_NNP 1200_CD mg_NN ,_, administered_VBN BID_NNP
        (_( APV_NNP 1200_CD )_) with_IN one_CD abacavir_NN 300_CD mg_NN tablet_NN and_CC one_CD
        lamivudine_NN 150_CD mg_NN /_NN zidovudine_NN 300_CD mg_NN combination_NN tablet_NN
        (_( Combivir_NNP ®_NN )_) ,_, was_VBD as_RB effective_JJ as_IN nelfinavir_NN 750_CD mg_NN three_CD
        times_NNS daily_JJ plus_CC Combivir_NNP BID_NNP ,_, with_IN regard_NN to_TO the_DT
        proportion_NN of_IN patients_NNS achieving_VBG HIV-_NNP 1_CD RNA_NNP <_NN 40_CD copies_NNS /_NN mL_NN
        at_IN week_NN 64_CD :_: 77_CD %_NN vs_NNS 66_CD %_NN (_( as-treated_JJ analysis_NN )_) [_NN 12_CD ]_NN ._.
        However_RB ,_, many_JJ patients_NNS in_IN this_DT trial_NN withdrew_VBD prematurely_RB
        because_IN of_IN adverse_JJ events_NNS that_WDT may_MD have_VB been_VBN ,_, in_IN part_NN ,_,
        related_VBN to_TO the_DT high_JJ pill_NN burden_NN (_( 16_CD large_JJ 150_CD mg_NN
        soft-gelatin_JJ capsules_NNS daily_JJ )_) associated_VBN with_IN APV_NNP dosing_VBG and_CC
        excipients_NNS contained_VBD in_IN the_DT APV_NNP formulation_NN available_JJ at_IN
        the_DT time_NN of_IN the_DT trial_NN ._.
        To_TO reduce_VB APV_NNP pill_NN burden_NN and_CC possibly_RB improve_VB
        tolerability_NN of_IN APV_NNP treatment_NN ,_, pharmacokinetic_JJ research_NN
        efforts_NNS have_VBP been_VBN directed_VBN at_IN combining_VBG APV_NNP with_IN the_DT PI_NNP
        ritonavir_NN (_( RTV_NNP )_) ,_, which_WDT inhibits_NNS CYP_NNP 3_CD A_DT 4_CD -_: mediated_JJ hepatic_JJ
        metabolism_NN of_IN APV_NNP ,_, thereby_RB enhancing_VBG plasma_NN APV_NNP exposure_NN [_NN
        13_CD 14_CD 15_CD ]_NN ._. The_DT administration_NN of_IN RTV_NNP at_IN the_DT clinically_RB
        sub-therapeutic_JJ dosage_NN of_IN 100_CD mg_NN BID_NNP was_VBD found_VBN to_TO boost_VB APV_NNP
        plasma_NN exposure_NN to_TO such_JJ a_DT degree_NN as_IN to_TO permit_VB halving_VBG the_DT
        APV_NNP daily_JJ pill_NN burden_NN from_IN 16_CD to_TO 8_CD capsules_NNS /_NN day_NN ,_, in_IN
        addition_NN to_TO maintaining_VBG the_DT minimum_JJ plasma_NN APV_NNP
        concentration_NN (_( C_NNP 
        min_NN )_) over_IN 24_CD hours_NNS well_RB above_IN the_DT 50_CD %_NN
        inhibitory_NN concentrations_NNS (_( IC_NNP 
        50_CD )_) of_IN patient-derived_JJ HIV-_NNP 1_CD isolates_VBZ [_NN
        15_CD ]_NN ._. A_DT pharmacokinetic_JJ study_NN in_IN 20_CD HIV-infected_NNP patients_NNS ,_,
        PROF_NNP 1004_CD ,_, showed_VBD that_IN APV_NNP at_IN the_DT lower_JJR dosage_NN of_IN 600_CD mg_NN BID_NNP
        combined_VBD with_IN RTV_NNP 100_CD mg_NN BID_NNP (_( APV_NNP 600_CD /_NN RTV_NNP )_) resulted_VBD in_IN a_DT
        geometric_JJ mean_NN steady-state_JJ APV_NNP C_NNP 
        min_NN (_( 1_CD ._. 92_CD μg_NN /_NN mL_NN )_) over_IN 6_CD -_: fold_VB higher_JJR than_IN
        the_DT C_NNP 
        min_NN resulting_VBG from_IN APV_NNP 1200_CD (_( 0_CD ._. 3_LS μg_NN /_NN mL_NN )_) [_NN
        16_CD ]_NN ._. This_DT C_NNP 
        min_NN was_VBD more_JJR than_IN 13_CD -_: fold_VB higher_JJR than_IN
        the_DT IC_NNP 
        50_CD of_IN APV_NNP against_IN HIV_NNP of_IN
        antiretroviral-naïve_JJ patients_NNS (_( mean_VB ,_, 0_CD ._. 146_CD ±_NN 0_CD ._. 125_CD μg_NN /_NN mL_NN )_)
        and_CC over_IN 2_CD -_: fold_VB higher_JJR than_IN the_DT IC_NNP 
        50_CD of_IN APV_NNP against_IN HIV_NNP of_IN
        multi-_NN PI-resistant_NNP patients_NNS (_( mean_VB ,_, 0_CD ._. 903_CD ±_NN 0_CD ._. 846_CD μg_NN /_NN mL_NN )_) (_( IC_NNP
        
        50_CD s_VBZ adjusted_VBN for_IN the_DT 90_CD %_NN protein_NN
        binding_JJ observed_VBD with_IN APV_NNP )_) ._. Following_VBG APV_NNP 600_CD /_NN RTV_NNP ,_, the_DT APV_NNP
        maximum_NN serum_NN concentration_NN (_( C_NNP 
        max_NN )_) has_VBZ been_VBN reported_VBN to_TO be_VB slightly_RB
        lower_JJR (_( by_IN 27_CD %_NN )_) than_IN that_DT observed_VBD with_IN APV_NNP 1200_CD [_NN 17_CD ]_NN ,_,
        which_WDT may_MD account_VB for_IN the_DT RTV-boosted_NNP APV_NNP regimen_NN being_VBG
        less_RBR likely_JJ to_TO cause_VB certain_JJ adverse_JJ events_NNS (_( e_SYM ._. g_SYM ._. ,_,
        oral_JJ /_NN perioral_NN paresthesia_NN and_CC headache_NN )_) [_NN 18_CD ]_NN ._.
        Since_IN the_DT above_JJ pharmacokinetic_JJ studies_NNS and_CC others_NNS
        involving_VBG pharmacokinetic_JJ modeling_NN predictions_NNS were_VBD
        conducted_VBN over_IN only_RB a_DT short_JJ period_NN (_( generally_RB ≤_NN 14_CD days_NNS )_)
        and_CC in_IN a_DT small_JJ number_NN of_IN patients_NNS ,_, there_EX remained_VBD a_DT need_NN to_TO
        evaluate_VB low-dose_JJ APV_NNP /_NN RTV_NNP combinations_NNS in_IN large_JJ populations_NNS
        of_IN HIV-_NNP 1_CD -_: infected_JJ patients_NNS over_IN a_DT therapeutically_RB relevant_JJ
        period_NN ._. The_DT purpose_NN of_IN ESS_NNP 40011_CD was_VBD to_TO compare_VB the_DT
        efficacy_NN ,_, safety_NN ,_, and_CC tolerability_NN of_IN APV_NNP 600_CD mg_NN BID_NNP plus_CC
        RTV_NNP 100_CD mg_NN BID_NNP (_( APV_NNP 600_CD /_NN RTV_NNP )_) to_TO APV_NNP 1200_CD mg_NN BID_NNP (_( APV_NNP 1200_CD )_)
        over_IN 24_CD weeks_NNS in_IN antiretroviral-naïve_JJ or_CC -_: experienced_VBN
        HIV-infected_NNP patients_NNS who_WP were_VBD receiving_VBG other_JJ background_NN
        antiretroviral_NN drugs_NNS ._. Late_RB in_IN the_DT study_NN ,_, patients_NNS who_WP had_VBD
        not_RB yet_RB completed_VBN 24_CD weeks_NNS of_IN treatment_NN were_VBD given_VBN the_DT
        option_NN to_TO continue_VB treatment_NN in_IN a_DT subsequent_JJ 24_CD -_: week_NN
        extension_NN phase_NN to_TO assess_VB the_DT durability_NN of_IN virologic_JJ
        response_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS
          Male_NN and_CC non-pregnant_JJ ,_, non-lactating_JJ female_JJ
          outpatients_NNS were_VBD eligible_JJ for_IN study_NN enrollment_NN if_IN they_PRP
          were_VBD at_IN least_JJS 18_CD years_NNS of_IN age_NN ;_: had_VBD HIV-_NNP 1_CD infection_NN
          documented_VBN by_IN HIV-_NNP 1_CD antibody_NN enzyme-linked_JJ immunosorbent_NN
          assay_NN (_( ELISA_NNP )_) and_CC confirmed_VBN by_IN Western_JJ blot_NN test_NN ,_,
          positive_JJ HIV-_NNP 1_CD culture_NN ,_, positive_JJ HIV-_NNP 1_CD serum_NN antigen_NN ,_, or_CC
          plasma_NN viremia_NN ;_: and_CC CD_NNP 4_CD +_NN cell_NN counts_VBZ ≥_NN 50_CD /_NN mm_NN 3_CD ._. Women_NNP of_IN
          childbearing_VBG potential_NN had_VBD to_TO have_VB a_DT negative_JJ serum_NN
          β-human_JJ chorionic_JJ gonadotropin_NN (_( HCG_NNP )_) pregnancy_NN test_NN at_IN
          screening_NN ,_, and_CC had_VBD to_TO be_VB willing_JJ to_TO use_VB an_DT adequate_JJ
          method_NN of_IN contraception_NN during_IN the_DT study_NN ._. Patients_NNS could_MD
          be_VB either_CC antiretroviral-naïve_JJ or_CC -_: experienced_VBN ._. If_IN
          patients_NNS were_VBD antiretroviral-experienced_JJ ,_, they_PRP had_VBD to_TO be_VB
          naïve_NN to_TO APV_NNP ,_, have_VBP a_DT plasma_NN HIV-_NNP 1_CD RNA_NNP >_NN 1000_CD copies_NNS /_NN mL_NN ,_,
          show_NN susceptibility_NN to_TO APV_NNP and_CC ≥_NN 2_CD other_JJ antiretroviral_NN
          drugs_NNS ,_, and_CC remain_VB on_IN their_PRP$ most_RBS recent_JJ treatment_NN regimen_NN
          until_IN completion_NN of_IN the_DT screening_NN visit_NN ._. For_IN all_DT drugs_NNS ,_,
          susceptibility_NN was_VBD defined_VBN as_IN an_DT HIV_NNP isolate_VB with_IN
          <_NN 4_CD ._. 0_CD -_: fold_VB change_NN in_IN IC_NNP 
          50_CD (_( determined_VBN by_IN VIRCOGEN_NNP ™_NN
          [_NN Tibotec-_NNP Virco_NNP NV_NNP ,_, Mechelen_NNP ,_, Belgium_NNP ]_NN ,_, a_DT virtual_JJ
          phenotype_NN assay_NN )_) in_IN comparison_NN to_TO the_DT control_NN virus_NN ._.
          Patients_NNS were_VBD excluded_VBN if_IN they_PRP had_VBD active_JJ Centers_NNPS for_IN
          Disease_NNP Control_NNP (_( CDC_NNP )_) Class_NN C_NNP status_NN ;_: could_MD not_RB comply_VB
          with_IN the_DT study_NN schedule_NN ;_: were_VBD in_IN another_DT investigational_JJ
          drug_NN study_NN ;_: were_VBD undergoing_VBG opiate_NN detoxification_NN ;_: had_VBD a_DT
          malabsorption_NN syndrome_NN or_CC pre-existing_JJ condition_NN that_WDT
          interfered_VBD with_IN normal_JJ gastrointestinal_NN transit_NN ;_: had_VBD
          clinically_RB significant_JJ laboratory_NN abnormalities_NNS ,_, required_VBN
          radiation_NN therapy_NN or_CC cytotoxic_JJ chemotherapy_NN ,_, or_CC had_VBD
          received_VBN immunomodulating_VBG agents_NNS ,_, within_IN 4_CD weeks_NNS
          pre-study_JJ ;_: or_CC had_VBD received_VBN an_DT HIV-_NNP 1_CD immunotherapeutic_JJ
          vaccine_NN within_IN 3_CD months_NNS pre-study_JJ ._. Patients_NNS were_VBD allowed_VBN
          to_TO take_VB pravastatin_NN ,_, fluvastatin_NN ,_, cerivastatin_NN ,_, or_CC
          atorvastatin_NN for_IN hyperlipidemia_NN at_IN the_DT cautionary_JJ
          discretion_NN of_IN the_DT investigators_NNS ,_, but_CC were_VBD not_RB allowed_VBN to_TO
          take_VB lovastatin_NN ,_, simvastatin_NN ,_, or_CC any_DT other_JJ drug_NN known_VBN to_TO
          significantly_RB affect_VB metabolism_NN by_IN the_DT cytochrome_NN P_NN 450_CD
          CYP_NNP 3_CD A_DT 4_CD enzyme_NN system_NN ._.
        
        
          Study_NNP Design_NNP
          In_IN this_DT multicenter_NN ,_, open-label_JJ clinical_JJ trial_NN ,_,
          patients_NNS were_VBD first_JJ stratified_JJ according_VBG to_TO prior_RB
          antiretroviral_NN therapy_NN exposure_NN (_( i_NNP ._. e_SYM ._. ,_, naïve_NN or_CC
          experienced_VBN )_) ,_, then_RB randomized_JJ 3_CD :_: 1_CD to_TO treatment_NN for_IN 24_CD
          weeks_NNS with_IN either_DT APV_NNP 600_CD mg_NN BID_NNP plus_CC RTV_NNP 100_CD mg_NN BID_NNP or_CC
          to_TO APV_NNP 1200_CD mg_NN BID_NNP in_IN combination_NN with_IN ≥_NN 2_CD non-_NN PI_NNP
          antiretroviral_NN drugs_NNS ._. APV_NNP was_VBD supplied_VBN as_IN 150_CD mg_NN
          soft-gelatin_JJ capsules_NNS of_IN Agenerase_NNP ®_NN (_( GlaxoSmithKline_NNP ,_,
          Research_NNP Triangle_NNP Park_NNP ,_, North_NNP Carolina_NNP )_) ;_: thus_RB ,_, eight_CD
          capsules_NNS were_VBD given_VBN for_IN each_DT 1200_CD mg_NN dose_NN of_IN APV_NNP and_CC four_CD
          capsules_NNS for_IN each_DT 600_CD mg_NN dose_NN ._. RTV_NNP was_VBD supplied_VBN as_IN 100_CD mg_NN
          soft-gelatin_JJ capsules_NNS of_IN Norvir_NNP ®_NN (_( Abbott_NNP Laboratories_NNPS ,_,
          North_NNP Chicago_NNP ,_, Illinois_NNP )_) ._. Late_RB in_IN the_DT study_NN ,_, patients_NNS who_WP
          had_VBD not_RB yet_RB completed_VBN 24_CD weeks_NNS of_IN treatment_NN were_VBD given_VBN
          the_DT option_NN to_TO continue_VB treatment_NN in_IN a_DT subsequent_JJ 24_CD -_: week_NN
          extension_NN phase_NN to_TO assess_VB the_DT durability_NN of_IN virologic_JJ
          response_NN ._.
          During_IN the_DT 6_CD -_: week_NN period_NN prior_RB to_TO the_DT start_NN of_IN the_DT
          study_NN ,_, candidates_NNS were_VBD screened_VBD for_IN study_NN eligibility_NN ,_,
          demography_NN ,_, CDC_NNP classification_NN ,_, HIV_NNP risk_NN factors_NNS ,_, mode_NN of_IN
          HIV_NNP transmission_NN ,_, antiretroviral_NN therapy_NN history_NN ,_, and_CC
          medical_JJ history_NN ,_, and_CC given_VBN a_DT physical_JJ examination_NN ._. Prior_RB
          to_TO study_VB initiation_NN ,_, the_DT ESS_NNP 40011_CD study_NN protocol_NN was_VBD
          approved_VBN by_IN the_DT Institutional_NNP Review_NNP Boards_NNP at_IN each_DT
          participating_VBG study_NN site_NN ._. All_DT participants_NNS provided_VBN
          written_VBN informed_VBN consent_NN before_IN any_DT study-related_JJ
          procedures_NNS were_VBD commenced_VBD ._. The_DT initial_JJ 24_CD -_: week_NN portion_NN of_IN
          the_DT study_NN was_VBD conducted_VBN between_IN June_NNP 13_CD ,_, 2000_CD and_CC October_NNP
          18_CD ,_, 2001_CD at_IN 44_CD treatment_NN centers_NNS in_IN the_DT United_NNP
          States_NNPS ._.
        
        
          Efficacy_NNP and_CC Safety_NNP Assessment_NNP
          The_DT primary_JJ efficacy_NN parameter_NN was_VBD the_DT proportion_NN of_IN
          patients_NNS with_IN plasma_NN HIV-_NNP 1_CD RNA_NNP levels_NNS <_NN 200_CD copies_NNS /_NN mL_NN
          at_IN week_NN 24_CD ._. Plasma_NNP HIV-_NNP 1_CD RNA_NNP was_VBD assessed_VBN by_IN the_DT Roche_NNP
          Amplicor_NNP MONITOR_NNP Ultrasensitive_NNP assay_NN (_( version_NN 1_CD ._. 5_CD ;_: lower_JJR
          limit_NN of_IN quantitation_NN [_NN LLOQ_NNP ]_NN 50_CD copies_NNS /_NN mL_NN and_CC
          quantitation_NN range_NN of_IN 50_CD to_TO 75_CD ,_, 000_CD copies_NNS /_NN mL_NN ,_, Roche_NNP
          Diagnostics_NNPS ,_, Branchburg_NNP ,_, New_NNP Jersey_NNP )_) ._. Patients_NNS were_VBD
          classified_VBN as_IN having_VBG reached_VBD a_DT virologic_JJ endpoint_NN if_IN ,_, at_IN
          week_NN 24_CD ,_, plasma_NN HIV-_NNP 1_CD RNA_NNP levels_NNS were_VBD ≥_NN 200_CD copies_NNS /_NN mL_NN ;_: or_CC
          if_IN the_DT plasma_NN HIV-_NNP 1_CD RNA_NNP had_VBD not_RB decreased_VBN by_IN at_IN least_JJS
          0_CD ._. 5_CD -_: log_VB 
          10_CD from_IN baseline_NN at_IN week_NN 8_CD ,_, with_IN
          confirmation_NN at_IN week_NN 12_CD ._.
          Secondary_JJ efficacy_NN measures_NNS included_VBD assessment_NN of_IN the_DT
          proportion_NN of_IN patients_NNS achieving_VBG HIV-_NNP 1_CD RNA_NNP <_NN 50_CD
          copies_NNS /_NN mL_NN (_( using_VBG the_DT above_JJ mentioned_VBN assay_NN )_) ;_: changes_NNS in_IN
          CD_NNP 4_CD +_NN cell_NN counts_VBZ (_( measured_VBN by_IN flow_NN cytometry_NN )_) compared_VBN
          with_IN baseline_NN values_NNS ;_: and_CC progression_NN of_IN HIV_NNP disease_NN from_IN
          baseline_NN status_NN to_TO the_DT occurrence_NN of_IN the_DT first_JJ new_JJ event_NN
          involving_VBG a_DT change_NN in_IN CDC_NNP class_NN for_IN each_DT patient_NN ._.
          Patients_NNS who_WP remained_VBD at_IN their_PRP$ entry_NN CDC_NNP class_NN were_VBD
          considered_VBN to_TO be_VB clinical_JJ non-progressors_JJ ._.
          Change_NNP from_IN baseline_NN in_IN plasma_NN HIV-_NNP 1_CD RNA_NNP levels_NNS was_VBD
          assessed_VBN at_IN weeks_NNS 4_CD ,_, 8_CD ,_, 12_CD ,_, and_CC 24_CD in_IN all_DT patients_NNS ,_, as_RB
          well_RB as_IN at_IN weeks_NNS 32_CD ,_, 40_CD and_CC 48_CD in_IN patients_NNS who_WP
          participated_VBD in_IN the_DT treatment_NN extension_NN phase_NN ._. CD_NNP 4_CD +_NN cell_NN
          counts_NNS were_VBD assessed_VBN at_IN baseline_NN ,_, and_CC at_IN weeks_NNS 12_CD and_CC 24_CD ._.
          Patients_NNS had_VBD plasma_NN collected_VBN for_IN genotype_NN /_NN virtual_JJ
          phenotype_NN at_IN screening_NN (_( for_IN experienced_VBN patients_NNS only_RB )_)
          and_CC at_IN the_DT time_NN of_IN virologic_JJ failure_NN (_( results_NNS to_TO be_VB
          reported_VBN elsewhere_RB )_) ._.
        
        
          Statistical_NNP Analysis_NNP
          The_DT study_NN was_VBD powered_VBN to_TO evaluate_VB whether_IN the_DT
          virologic_JJ efficacy_NN (_( proportion_NN of_IN patients_NNS with_IN plasma_NN
          HIV-_NNP 1_CD HIV_NNP <_NN 200_CD copies_NNS /_NN mL_NN at_IN week_NN 24_CD )_) in_IN the_DT APV_NNP
          600_CD /_NN RTV_NNP arm_NN was_VBD at_IN least_JJS as_IN good_JJ (_( non-inferior_JJ )_) as_IN in_IN the_DT
          APV_NNP 1200_CD arm_NN ._. Non-inferiority_NNP of_IN the_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN to_TO
          the_DT APV_NNP 1200_CD regimen_NN was_VBD established_VBN if_IN the_DT 95_CD %_NN lower_JJR
          confidence_NN limit_NN (_( LCL_NNP )_) for_IN the_DT difference_NN in_IN proportion_NN
          of_IN patients_NNS achieving_VBG HIV-_NNP 1_CD RNA_NNP <_NN 200_CD copies_NNS /_NN mL_NN at_IN week_NN
          24_CD with_IN APV_NNP 600_CD /_NN RTV_NNP minus_CC APV_NNP 1200_CD was_VBD ≥_NN -_: 0_CD ._. 12_CD ._. The_DT
          non-inferiority_JJ margin_NN of_IN 0_CD ._. 12_CD was_VBD chosen_VBN based_VBN on_IN
          previous_JJ regulatory_JJ studies_NNS and_CC was_VBD pre-specified_JJ in_IN the_DT
          protocol_NN ._. Target_NNP enrollment_NN was_VBD 198_CD in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN
          and_CC 66_CD in_IN the_DT APV_NNP 1200_CD arm_NN ._. The_DT primary_JJ analysis_NN was_VBD made_VBN
          in_IN the_DT intent-to-treat_JJ (_( ITT_NNP )_) population_NN ,_, which_WDT consisted_VBD
          of_IN all_DT eligible_JJ patients_NNS who_WP were_VBD randomized_JJ into_IN the_DT
          study_NN regardless_RB of_IN what_WP treatment_NN was_VBD actually_RB received_VBN
          and_CC the_DT eventual_JJ outcome_NN of_IN study_NN participation_NN ._. Two_CD
          types_NNS of_IN analyses_NNS were_VBD performed_VBN :_: an_DT ITT_NNP :_: observed_VBD
          analysis_NN ,_, in_IN which_WDT only_RB available_JJ assessments_NNS were_VBD used_VBN
          (_( no_DT imputation_NN for_IN missing_VBG values_NNS )_) ,_, regardless_RB of_IN whether_IN
          the_DT patient_NN was_VBD still_RB receiving_VBG their_PRP$ original_JJ therapy_NN ;_:
          and_CC an_DT ITT_NNP :_: missing_VBG =_SYM failure_NN (_( ITT_NNP :_: M_NNP =_SYM F_NN )_) analysis_NN ,_, in_IN
          which_WDT all_DT missing_VBG values_NNS constituted_VBD failure_NN ._. Comparisons_NNP
          between_IN treatment_NN arms_NNS regarding_VBG proportion_NN of_IN patients_NNS
          achieving_VBG HIV-_NNP 1_CD RNA_NNP <_NN 200_CD copies_NNS /_NN mL_NN and_CC <_NN 50_CD
          copies_NNS /_NN mL_NN were_VBD made_VBN using_VBG the_DT Cochran-_NNP Mantel-_NNP Haenszel_NNP
          test_NN controlling_VBG for_IN prior_JJ antiretroviral_NN drug_NN
          experience_NN ._. Changes_NNS from_IN baseline_NN in_IN plasma_NN HIV-_NNP 1_CD RNA_NNP
          (_( log_VB 
          10_CD copies_NNS /_NN mL_NN )_) and_CC CD_NNP 4_CD +_NN cell_NN count_NN ,_, and_CC
          average_JJ area_NN under_IN the_DT curve_NN minus_CC baseline_NN (_( AAUCMB_NNP )_) in_IN
          plasma_NN HIV-_NNP 1_CD RNA_NNP ,_, were_VBD tabulated_JJ by_IN treatment_NN arm_NN and_CC
          visit_NN ,_, then_RB analyzed_VBD using_VBG analysis_NN of_IN variance_NN (_( ANOVA_NNP )_) ._.
          The_DT safety_NN population_NN consisted_VBD of_IN all_DT patients_NNS who_WP
          consumed_VBD at_IN least_JJS 1_CD dose_NN of_IN study_NN drug_NN ._. Safety_NN parameters_NNS
          included_VBD incidence_NN of_IN treatment-limiting_JJ toxicities_NNS
          (_( clinical_JJ and_CC laboratory_NN adverse_JJ events_NNS )_) ;_: and_CC change_NN from_IN
          baseline_NN in_IN selected_VBN laboratory_NN variables_NNS at_IN weeks_NNS 4_CD ,_, 8_CD ,_,
          12_CD and_CC 24_CD ._. Fisher_NNP 's_POS exact_JJ test_NN was_VBD used_VBN to_TO compare_VB
          adverse_JJ event_NN rate_NN and_CC ANOVA_NNP was_VBD used_VBN to_TO compare_VB change_NN
          from_IN baseline_NN for_IN laboratory_NN variables_NNS between_IN the_DT two_CD
          treatment_NN arms_NNS ._. A_DT 
          P_NN value_NN of_IN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._. Statistical_NNP analyses_NNS were_VBD
          performed_VBN using_VBG SAS_NNP version_NN 6_CD ._. 12_CD (_( SAS_NNP Institute_NNP ,_, Inc_NNP ._. ,_,
          Cary_NNP ,_, NC_NNP )_) ._.
        
      
      
        Results_NNS
        
          Patient_NNP Characteristics_NNP and_CC Disposition_NNP
          A_DT total_NN of_IN 211_CD patients_NNS enrolled_VBD ;_: they_PRP were_VBD
          predominantly_RB male_JJ (_( 87_CD %_NN )_) ,_, ethnically_RB diverse_JJ (_( 48_CD %_NN
          Caucasian_NNP ,_, 37_CD %_NN African_NNP American_NNP ,_, 14_CD %_NN Hispanic_JJ )_) ,_, and_CC had_VBD a_DT
          mean_JJ age_NN of_IN 42_CD years_NNS ,_, median_JJ baseline_NN HIV-_NNP 1_CD RNA_NNP level_NN of_IN
          4_CD ._. 33_CD log_VB 
          10_CD copies_NNS /_NN mL_NN ,_, and_CC median_JJ baseline_NN CD_NNP 4_CD +_NN
          cell_NN count_NN of_IN 257_CD cells_NNS /_NN mm_NN 3_CD ._. Most_JJS of_IN the_DT study_NN
          population_NN was_VBD antiretroviral-experienced_JJ (_( 81_CD %_NN )_) ._. One_CD
          hundred_CD and_CC fifty-eight_JJ (_( 158_CD )_) patients_NNS were_VBD randomized_JJ to_TO
          the_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN and_CC 53_CD to_TO the_DT APV_NNP 1200_CD regimen_NN ._. The_DT
          two_CD treatment_NN arms_NNS did_VBD not_RB differ_VB with_IN respect_NN to_TO any_DT
          baseline_NN characteristic_JJ (_( Table_NNP 1_LS )_) ._. The_DT most_RBS common_JJ
          background_NN antiretroviral_NN regimens_NNS taken_VBN by_IN patients_NNS in_IN
          the_DT APV_NNP 600_CD /_NN RTV_NNP and_CC APV_NNP 1200_CD treatment_NN arms_NNS were_VBD
          stavudine_NN /_NN didanosine_NN (_( 25_CD %_NN vs_NNS 30_CD %_NN )_) ,_, Combivir_NNP (_( 19_CD %_NN for_IN both_DT
          arms_NNS )_) ,_, abacavir_NN /_NN stavudine_NN (_( 11_CD %_NN for_IN both_DT arms_NNS )_) ,_,
          lamivudine_NN /_NN stavudine_NN (_( 9_CD %_NN vs_NNS 4_CD %_NN )_) ,_, and_CC abacavir_NN /_NN didanosine_NN
          (_( 5_CD %_NN vs_NNS 6_CD %_NN )_) ._. A_DT total_NN of_IN 150_CD patients_NNS (_( 71_CD %_NN )_) completed_VBD all_DT
          24_CD weeks_NNS of_IN the_DT study_NN ,_, including_VBG a_DT similar_JJ proportion_NN of_IN
          patients_NNS in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN (_( 72_CD %_NN )_) and_CC APV_NNP 1200_CD arm_NN
          (_( 68_CD %_NN )_) ._. Reasons_NNS for_IN premature_JJ withdrawal_NN from_IN treatment_NN
          were_VBD also_RB similar_JJ between_IN the_DT APV_NNP 600_CD /_NN RTV_NNP and_CC APV_NNP 1200_CD
          arms_NNS ,_, except_IN for_IN fewer_JJR patients_NNS in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN
          withdrawing_VBG due_JJ to_TO protocol-defined_JJ virologic_JJ failure_NN (_( 1_CD %_NN
          vs_NNS 6_CD %_NN )_) (_( Table_NNP 1_LS )_) ._. Antihyperlipidemic_NNP agents_NNS were_VBD used_VBN by_IN
          1_CD patient_NN in_IN each_DT treatment_NN arm_NN ,_, neither_DT of_IN whom_WP had_VBD
          taken_VBN this_DT type_NN of_IN medication_NN pre-study_JJ ._. No_DT deaths_NNS or_CC
          clinical_JJ progressions_NNS of_IN HIV_NNP disease_NN occurred_VBD ._. Twenty_CD
          patients_NNS enrolled_VBD into_IN the_DT extension_NN phase_NN ,_, including_VBG 15_CD
          in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN and_CC 5_CD in_IN the_DT APV_NNP 1200_CD arm_NN ._.
        
        
          Virologic_NNP Measurements_NNP of_IN Efficacy_NNP
          At_IN week_NN 24_CD ,_, the_DT proportion_NN of_IN patients_NNS with_IN HIV-_NNP 1_CD RNA_NNP
          <_NN 200_CD copies_NNS /_NN mL_NN in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN and_CC APV_NNP 1200_CD arm_NN
          was_VBD 46_CD %_NN (_( 73_CD /_NN 158_CD )_) and_CC 38_CD %_NN (_( 20_CD /_NN 53_CD )_) ,_, respectively_RB ,_, in_IN the_DT
          ITT_NNP :_: M_NNP =_SYM F_NN analysis_NN (_( Figure_NN 1_LS )_) and_CC 62_CD %_NN (_( 73_CD /_NN 118_CD )_) and_CC 53_CD %_NN
          (_( 20_CD /_NN 38_CD )_) ,_, respectively_RB ,_, in_IN the_DT ITT_NNP :_: observed_VBD analysis_NN
          (_( Figure_NN 2_LS )_) ._. The_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN proved_VBD to_TO be_VB similar_JJ
          to_TO or_CC better_JJR than_IN the_DT APV_NNP 1200_CD regimen_NN because_IN the_DT 95_CD %_NN LCL_NNP
          for_IN the_DT difference_NN in_IN proportions_NNS of_IN patients_NNS achieving_VBG
          HIV-_NNP 1_CD RNA_NNP <_NN 200_CD copies_NNS /_NN mL_NN with_IN APV_NNP 600_CD /_NN RTV_NNP minus_CC APV_NNP 1200_CD
          was_VBD ≥_NN -_: 0_CD ._. 12_CD (_( -_: 0_CD ._. 04_CD [_NN ITT_NNP :_: M_NNP =_SYM F_NN analysis_NN ]_NN and_CC -_: 0_CD ._. 06_CD [_NN ITT_NNP :_:
          observed_VBD analysis_NN ]_NN )_) ._. The_DT proportion_NN of_IN
          antiretroviral-naïve_JJ patients_NNS who_WP achieved_VBD HIV-_NNP 1_CD RNA_NNP
          <_NN 200_CD copies_NNS /_NN mL_NN in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN was_VBD twice_RB that_IN
          for_IN the_DT APV_NNP 1200_CD arm_NN in_IN the_DT ITT_NNP :_: M_NNP =_SYM F_NN analysis_NN (_( 63_CD %_NN
          [_NN 19_CD /_NN 30_CD ]_NN vs_NNS 30_CD %_NN [_NN 3_CD /_NN 10_CD ]_NN ,_, 
          P_NN =_SYM 0_CD ._. 141_CD )_) ,_, and_CC 26_CD %_NN higher_JJR in_IN the_DT
          ITT_NNP :_: observed_VBD analysis_NN (_( 76_CD %_NN [_NN 19_CD /_NN 25_CD ]_NN vs_NNS 50_CD %_NN [_NN 3_CD /_NN 6_CD ]_NN ,_, 
          P_NN =_SYM 0_CD ._. 320_CD )_) ._. In_IN contrast_NN ,_, the_DT
          proportions_NNS in_IN antiretroviral-experienced_JJ patients_NNS were_VBD
          similar_JJ in_IN the_DT treatment_NN arms_NNS in_IN both_DT analyses_NNS (_( ITT_NNP :_: M_NNP =_SYM
          F_NN analysis_NN :_: 42_CD %_NN [_NN 54_CD /_NN 128_CD ]_NN vs_NNS 40_CD %_NN [_NN 17_CD /_NN 43_CD ]_NN ,_, 
          P_NN =_SYM 0_CD ._. 859_CD ;_: ITT_NNP :_: observed_VBD analysis_NN :_:
          58_CD %_NN [_NN 54_CD /_NN 93_CD ]_NN vs_NNS 53_CD %_NN [_NN 17_CD /_NN 32_CD ]_NN ,_, 
          P_NN =_SYM 0_CD ._. 682_CD )_) ._.
          Virologic_NNP findings_NNS using_VBG the_DT more_RBR stringent_JJ virologic_JJ
          suppression_NN endpoint_NN of_IN HIV-_NNP 1_CD RNA_NNP <_NN 50_CD copies_NNS /_NN mL_NN
          paralleled_JJ those_DT with_IN the_DT <_NN 200_CD copies_NNS /_NN mL_NN endpoint_NN ,_,
          although_IN differences_NNS attained_VBN statistical_JJ significance_NN ._.
          Thus_RB ,_, at_IN week_NN 24_CD ,_, significantly_RB more_JJR patients_NNS in_IN the_DT
          APV_NNP 600_CD /_NN RTV_NNP arm_NN than_IN the_DT APV_NNP 1200_CD arm_NN achieved_VBD HIV-_NNP 1_CD RNA_NNP
          <_NN 50_CD copies_NNS /_NN mL_NN (_( ITT_NNP :_: M_NNP =_SYM F_NN analysis_NN :_: 36_CD %_NN [_NN 57_CD /_NN 158_CD ]_NN vs_NNS
          21_CD %_NN [_NN 11_CD /_NN 53_CD ]_NN ,_, 
          P_NN =_SYM 0_CD ._. 039_CD ;_: ITT_NNP :_: observed_VBD analysis_NN :_:
          48_CD %_NN [_NN 57_CD /_NN 118_CD ]_NN vs_NNS 29_CD %_NN [_NN 11_CD /_NN 38_CD ]_NN ,_, 
          P_NN =_SYM 0_CD ._. 042_CD )_) (_( Figures_NNS 1_CD and_CC 2_CD ,_,
          respectively_RB )_) ._. The_DT proportion_NN of_IN antiretroviral-naïve_JJ
          patients_NNS who_WP achieved_VBD HIV-_NNP 1_CD RNA_NNP <_NN 50_CD copies_NNS /_NN mL_NN was_VBD 47_CD %_NN
          (_( 14_CD /_NN 30_CD )_) in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN and_CC 20_CD %_NN (_( 2_CD /_NN 10_CD )_) in_IN the_DT
          APV_NNP 1200_CD arm_NN (_( 
          P_NN =_SYM 0_CD ._. 141_CD )_) ,_, whereas_IN the_DT proportion_NN
          of_IN antiretroviral-experienced_JJ patients_NNS who_WP achieved_VBD HIV-_NNP 1_CD
          RNA_NNP <_NN 50_CD copies_NNS /_NN mL_NN was_VBD 34_CD %_NN (_( 43_CD /_NN 128_CD )_) in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP
          arm_NN and_CC 21_CD %_NN (_( 9_CD /_NN 43_CD )_) in_IN the_DT APV_NNP 1200_CD arm_NN (_( 
          P_NN =_SYM 0_CD ._. 119_CD )_) (_( ITT_NNP :_: M_NNP =_SYM F_NN analysis_NN )_) ._. In_IN
          the_DT ITT_NNP :_: observed_VBD analysis_NN ,_, mean_VB reduction_NN in_IN HIV-_NNP 1_CD RNA_NNP
          from_IN baseline_NN was_VBD significantly_RB greater_JJR at_IN week_NN 24_CD in_IN the_DT
          APV_NNP 600_CD /_NN RTV_NNP arm_NN than_IN the_DT APV_NNP 1200_CD arm_NN (_( -_: 2_CD ._. 21_CD vs_NNS -_: 1_CD ._. 59_CD log_VB 
          10_CD copies_NNS /_NN mL_NN ,_, 
          P_NN =_SYM 0_CD ._. 028_CD )_) (_( Figure_NN 3_LS )_) ,_, as_IN was_VBD the_DT
          mean_NN AAUCMB_NNP in_IN HIV-_NNP 1_CD RNA_NNP in_IN both_DT the_DT total_JJ population_NN
          (_( -_: 1_CD ._. 56_CD vs_NNS -_: 1_CD ._. 25_CD log_VB 
          10_CD copies_NNS /_NN mL_NN ,_, 
          P_NN =_SYM 0_CD ._. 045_CD )_) and_CC antiretroviral-naïve_JJ
          subgroup_NN (_( -_: 2_CD ._. 40_CD vs_NNS -_: 1_CD ._. 60_CD log_VB 
          10_CD copies_NNS /_NN mL_NN ,_, 
          P_NN =_SYM 0_CD ._. 020_CD )_) ._. No_DT significant_JJ
          differences_NNS were_VBD observed_VBN between_IN the_DT APV_NNP 600_CD /_NN RTV_NNP and_CC
          APV_NNP 1200_CD treatment_NN arms_NNS with_IN respect_NN to_TO mean_VB AAUCMB_NNP in_IN
          HIV-_NNP 1_CD RNA_NNP for_IN the_DT antiretroviral-experienced_JJ subgroup_NN
          (_( -_: 1_CD ._. 40_CD vs_NNS -_: 1_CD ._. 20_CD log_VB 
          10_CD copies_NNS /_NN mL_NN 
          P_NN =_SYM 0_CD ._. 209_CD )_) ,_, or_CC proportion_NN of_IN
          antiretroviral-naïve_JJ patients_NNS achieving_VBG HIV-_NNP 1_CD RNA_NNP <_NN 50_CD
          copies_NNS /_NN mL_NN (_( 56_CD %_NN vs_NNS 33_CD %_NN ,_, 
          P_NN =_SYM 0_CD ._. 394_CD )_) (_( ITT_NNP :_: observed_VBD
          analysis_NN )_) ._.
          Of_IN the_DT 20_CD patients_NNS (_( 15_CD in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN and_CC 5_CD in_IN
          the_DT APV_NNP 1200_CD arm_NN )_) enrolled_VBD into_IN the_DT extension_NN phase_NN ,_, 15_CD
          (_( 11_CD APV_NNP 600_CD /_NN RTV_NNP ,_, 4_CD APV_NNP 1200_CD )_) had_VBD HIV-_NNP 1_CD RNA_NNP <_NN 200_CD
          copies_NNS /_NN mL_NN at_IN week_NN 24_CD ._. Eleven_CD (_( 8_CD APV_NNP 600_CD /_NN RTV_NNP ,_, 3_CD APV_NNP 1200_CD )_) of_IN
          these_DT 15_CD patients_NNS continued_VBD to_TO have_VB HIV-_NNP 1_CD RNA_NNP levels_NNS
          <_NN 200_CD copies_NNS /_NN mL_NN between_IN week_NN 24_CD and_CC week_NN 48_CD ,_, 3_CD
          rebounded_VBD ,_, and_CC 1_CD discontinued_VBN at_IN week_NN 32_CD ._. Of_IN the_DT 5_CD
          patients_NNS who_WP had_VBD HIV-_NNP 1_CD RNA_NNP >_NN 200_CD copies_NNS /_NN mL_NN at_IN week_NN 24_CD ,_,
          1_CD discontinued_VBN when_WRB an_DT HIV-_NNP 1_CD RNA_NNP of_IN 186_CD copies_NNS /_NN mL_NN was_VBD
          measured_VBN at_IN week_NN 32_CD ,_, 1_CD missed_VBD week_NN 32_CD and_CC 40_CD visits_NNS (_( but_CC
          had_VBD an_DT HIV-_NNP 1_CD RNA_NNP of_IN 878_CD copies_NNS /_NN mL_NN at_IN week_NN 48_CD )_) ,_, and_CC 3_CD
          continued_VBD to_TO have_VB HIV-_NNP 1_CD RNA_NNP >_NN 200_CD copies_NNS /_NN mL_NN from_IN week_NN
          24_CD to_TO week_NN 48_CD ._. In_IN these_DT 3_CD patients_NNS ,_, HIV-_NNP 1_CD RNA_NNP levels_NNS
          ranged_VBD from_IN 316_CD to_TO 3645_CD copies_NNS /_NN mL_NN ,_, 1247_CD to_TO 5175_CD
          copies_NNS /_NN mL_NN ,_, and_CC 143_CD to_TO 12_CD ,_, 149_CD copies_NNS /_NN mL_NN ,_, respectively_RB ,_,
          between_IN weeks_NNS 24_CD and_CC 48_CD ._.
        
        
          Immunologic_NNP Measurements_NNP of_IN Efficacy_NNP
          At_IN baseline_NN ,_, the_DT median_JJ CD_NNP 4_CD +_NN cell_NN count_NN in_IN the_DT
          APV_NNP 600_CD /_NN RTV_NNP and_CC APV_NNP 1200_CD arms_NNS was_VBD 271_CD and_CC 255_CD cells_NNS /_NN mm_NN 3_CD ,_,
          respectively_RB ._. Over_IN the_DT 24_CD weeks_NNS of_IN the_DT study_NN ,_, the_DT median_JJ
          CD_NNP 4_CD +_NN cell_NN count_NN remained_VBD higher_JJR than_IN baseline_NN ,_, with_IN
          median_JJ elevations_NNS above_IN baseline_NN peaking_VBG at_IN week_NN 12_CD in_IN
          both_DT treatment_NN arms_NNS (_( +_NN 51_CD and_CC +_NN 52_CD cells_NNS /_NN mm_NN 3_CD ,_,
          respectively_RB )_) (_( Figure_NN 3_LS )_) ._. At_IN week_NN 24_CD ,_, the_DT median_JJ change_NN
          from_IN baseline_NN in_IN CD_NNP 4_CD +_NN cell_NN count_NN in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP and_CC
          APV_NNP 1200_CD arms_NNS was_VBD +_NN 35_CD and_CC +_NN 46_CD cells_NNS /_NN mm_NN 3_CD ,_, respectively_RB ,_,
          and_CC the_DT final_JJ median_JJ CD_NNP 4_CD +_NN cell_NN count_NN was_VBD 321_CD and_CC 346_CD
          cells_NNS /_NN mm_NN 3_CD ,_, respectively_RB ._. In_IN patients_NNS who_WP participated_VBD in_IN
          the_DT 24_CD -_: week_NN extension_NN phase_NN ,_, 12_CD of_IN 15_CD patients_NNS in_IN the_DT
          APV_NNP 600_CD /_NN RTV_NNP arm_NN and_CC 4_CD of_IN 5_CD in_IN the_DT APV_NNP 1200_CD arm_NN had_VBD a_DT median_JJ
          change_NN from_IN baseline_NN in_IN CD_NNP 4_CD +_NN cell_NN count_NN at_IN week_NN 48_CD of_IN
          +_NN 156_CD cell_NN /_NN mm_NN 3_CD ,_, and_CC +_NN 143_CD cell_NN /_NN mm_NN 3_CD ,_, respectively_RB ._. The_DT
          final_JJ median_JJ CD_NNP 4_CD +_NN cell_NN count_NN in_IN these_DT patients_NNS was_VBD 404_CD
          and_CC 407_CD cells_NNS /_NN mm_NN 3_CD ,_, respectively_RB ._. The_DT remaining_VBG patients_NNS
          did_VBD not_RB have_VB CD_NNP 4_CD +_NN data_NNS reported_VBD ._.
        
        
          Safety_NNP
          Table_NNP 2_CD shows_VBZ the_DT drug-related_JJ adverse_JJ events_NNS that_WDT were_VBD
          reported_VBN in_IN ≥_NN 5_CD %_NN of_IN patients_NNS ._. Nausea_NN ,_, diarrhea_NN ,_, vomiting_NN ,_,
          and_CC fatigue_NN were_VBD the_DT most_RBS common_JJ adverse_JJ events_NNS in_IN both_DT
          treatment_NN arms_NNS ._. The_DT incidence_NN of_IN drug-related_JJ
          oral_JJ /_NN perioral_NN paresthesia_NN was_VBD lower_JJR in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP
          treatment_NN arm_NN than_IN the_DT APV_NNP 1200_CD arm_NN (_( 2_CD %_NN vs_NNS 8_CD %_NN )_) ._. No_DT
          differences_NNS between_IN the_DT APV_NNP 600_CD /_NN RTV_NNP and_CC APV_NNP 1200_CD treatment_NN
          arms_NNS were_VBD observed_VBN regarding_VBG the_DT frequency_NN of_IN
          drug-related_JJ grade_NN 1_CD -_: 4_CD adverse_JJ events_NNS (_( 44_CD %_NN vs_NNS 45_CD %_NN )_) ,_,
          frequency_NN of_IN discontinuing_VBG treatment_NN due_JJ to_TO adverse_JJ
          events_NNS (_( 7_CD %_NN vs_NNS 8_CD %_NN )_) ,_, incidence_NN of_IN hyperglycemia_NN (_( 1_CD vs_NNS 0_CD
          patient_NN )_) ,_, nonspecific_JJ lipodystrophy_NN (_( 1_CD vs_NNS 0_CD )_) ,_, buffalo_NN
          hump_NN (_( 1_CD vs_NNS 0_CD )_) ,_, or_CC hypercholesterolemia_NN (_( 1_CD vs_NNS 0_CD )_) ._. More_JJR
          cases_NNS of_IN hypertriglyceridemia_NN were_VBD reported_VBN as_IN adverse_JJ
          events_NNS in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN (_( 11_CD [_NN 7_CD %_NN ]_NN vs_NNS 0_CD )_) ._. However_RB ,_,
          review_NN of_IN laboratory_NN changes_NNS revealed_VBD that_IN the_DT incidence_NN
          of_IN grade_NN 3_CD -_: 4_CD hypertriglyceridemia_NN was_VBD the_DT same_JJ (_( 4_CD %_NN )_) in_IN
          each_DT treatment_NN arm_NN ._.
        
      
      
        Discussion_NNP
        The_DT virological_JJ results_NNS of_IN this_DT study_NN indicate_VBP that_IN over_IN
        a_DT 24_CD -_: week_NN treatment_NN period_NN the_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN was_VBD
        statistically_RB similar_JJ to_TO or_CC better_JJR than_IN the_DT APV_NNP 1200_CD regimen_NN
        according_VBG to_TO the_DT <_NN 200_CD copies_NNS /_NN mL_NN endpoint_NN criterion_NN ._.
        However_RB ,_, a_DT significantly_RB greater_JJR proportion_NN of_IN patients_NNS in_IN
        the_DT APV_NNP 600_CD /_NN RTV_NNP treatment_NN arm_NN achieved_VBD HIV-_NNP 1_CD RNA_NNP <_NN 50_CD
        copies_NNS /_NN mL_NN ._. Greater_NNP reductions_NNS in_IN plasma_NN HIV-_NNP 1_CD RNA_NNP levels_NNS
        were_VBD also_RB observed_VBN in_IN patients_NNS receiving_VBG APV_NNP 600_CD /_NN RTV_NNP BID_NNP
        than_IN those_DT using_VBG APV_NNP 1200_CD BID_NNP ._. The_DT greater_JJR magnitude_NN of_IN
        virologic_JJ suppression_NN in_IN the_DT study_NN population_NN as_IN a_DT whole_NN
        with_IN the_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN was_VBD expected_VBN in_IN view_NN of_IN the_DT
        results_NNS of_IN earlier_RBR clinical_JJ pharmacokinetic_JJ studies_NNS showing_VBG
        a_DT >_NN 6_CD -_: fold_VB higher_JJR C_NNP 
        min_NN level_NN with_IN APV_NNP 600_CD /_NN RTV_NNP BID_NNP compared_VBD
        with_IN the_DT APV_NNP 1200_CD BID_NNP regimen_NN [_NN 16_CD ]_NN ._. Higher_JJR C_NNP 
        min_NN values_NNS achieved_VBN with_IN RTV-boosting_NNP
        may_MD be_VB critical_JJ in_IN treating_VBG antiretroviral-experienced_JJ
        patients_NNS ,_, particularly_RB those_DT with_IN HIV_NNP isolates_VBZ having_VBG
        increased_VBN IC_NNP 
        50_CD values_NNS ._.
        The_DT proportion_NN of_IN antiretroviral-naïve_JJ patients_NNS who_WP
        achieved_VBD HIV-_NNP 1_CD RNA_NNP <_NN 200_CD copies_NNS /_NN mL_NN in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN
        was_VBD twice_RB that_IN for_IN the_DT APV_NNP 1200_CD arm_NN (_( 63_CD %_NN vs_NNS 30_CD %_NN ,_, 
        P_NN =_SYM 0_CD ._. 141_CD )_) ._. No_DT differences_NNS in_IN
        virologic_JJ efficacy_NN between_IN treatment_NN arms_NNS were_VBD evident_JJ in_IN
        the_DT antiretroviral-experienced_JJ subgroup_NN (_( 42_CD %_NN vs_NNS 40_CD %_NN ,_, 
        P_NN =_SYM 0_CD ._. 859_CD )_) ._. It_PRP is_VBZ possible_JJ that_IN
        proportionally_RB more_RBR treatment-naïve_JJ patients_NNS may_MD have_VB
        responded_VBN to_TO APV_NNP 600_CD /_NN RTV_NNP due_JJ to_TO poorer_JJR or_CC more_RBR difficult_JJ
        adherence_NN to_TO the_DT APV_NNP 1200_CD regimen_NN ,_, but_CC no_DT adherence_NN checks_NNS
        were_VBD included_VBN in_IN this_DT study_NN to_TO verify_VB this_DT ._. Although_IN the_DT
        <_NN 50_CD copies_NNS /_NN mL_NN endpoint_NN criterion_NN also_RB showed_VBD a_DT higher_JJR
        proportion_NN of_IN antiretroviral-naïve_JJ patients_NNS responding_VBG to_TO
        APV_NNP 600_CD /_NN RTV_NNP than_IN to_TO APV_NNP 1200_CD (_( 47_CD %_NN vs_NNS 20_CD %_NN )_) ,_, the_DT differences_NNS
        were_VBD not_RB statistically_RB significant_JJ ,_, possibly_RB due_JJ to_TO the_DT
        small_JJ size_NN of_IN this_DT subgroup_NN ._. In_IN another_DT study_NN of_IN APV_NNP 600_CD /_NN RTV_NNP
        in_IN antiretroviral-naïve_JJ patients_NNS ,_, Arasteh_NNP et_CC al_NN [_NN 19_CD ]_NN
        reported_VBD a_DT higher_JJR proportion_NN of_IN patients_NNS achieving_VBG plasma_NN
        HIV-_NNP 1_CD RNA_NNP <_NN 50_CD copies_NNS /_NN mL_NN (_( 75_CD %_NN )_) than_IN in_IN the_DT present_JJ study_NN ,_,
        perhaps_RB due_JJ to_TO the_DT use_NN of_IN only_RB lamivudine_NN and_CC abacavir_NN as_IN
        background_NN antiretroviral_NN medication_NN and_CC to_TO differences_NNS in_IN
        their_PRP$ study_NN population_NN relative_JJ to_TO ours_PRP ._.
        The_DT proportion_NN of_IN antiretroviral-experienced_JJ patients_NNS in_IN
        the_DT APV_NNP 600_CD /_NN RTV_NNP treatment_NN arm_NN who_WP achieved_VBD HIV-_NNP 1_CD RNA_NNP <_NN 200_CD
        copies_NNS /_NN mL_NN at_IN 24_CD weeks_NNS (_( 58_CD %_NN [_NN ITT_NNP :_: observed_VBD analysis_NN ]_NN ;_: 42_CD %_NN
        [_NN ITT_NNP :_: M_NNP =_SYM F_NN analysis_NN ]_NN )_) was_VBD comparable_JJ to_TO that_DT reported_VBD in_IN
        antiretroviral-experienced_JJ patients_NNS at_IN 24_CD weeks_NNS in_IN the_DT
        studies_NNS by_IN Schooley_NNP et_CC al_NN [_NN 20_CD ]_NN (_( ESS_NNP 40006_CD [_NN PEARL_NNP ]_NN )_) (_( 69_CD %_NN
        [_NN ITT_NNP :_: observed_VBD analysis_NN ]_NN )_) ,_, but_CC much_RB higher_JJR than_IN that_DT
        reported_VBN by_IN Katlama_NNP et_CC al_NN [_NN 21_CD ]_NN (_( 31_CD %_NN [_NN ITT_NNP :_: M_NNP =_SYM F_NN
        analysis_NN ]_NN )_) ._. Differences_NNS in_IN virologic_JJ suppression_NN between_IN
        the_DT present_JJ study_NN and_CC the_DT Katlama_NNP study_NN may_MD stem_VB from_IN the_DT
        use_NN of_IN other_JJ background_NN agents_NNS and_CC the_DT far_RB greater_JJR
        antiretroviral_NN experience_NN and_CC well-documented_JJ PI_NNP mutations_NNS
        in_IN Katlama_NNP 's_POS patients_NNS ._.
        The_DT 24_CD -_: week_NN extension_NN phase_NN showed_VBD that_IN most_JJS patients_NNS
        who_WP had_VBD HIV-_NNP 1_CD RNA_NNP <_NN 200_CD copies_NNS /_NN mL_NN at_IN week_NN 24_CD maintained_VBD
        this_DT level_NN of_IN virologic_JJ suppression_NN through_IN week_NN 48_CD ._. Thus_RB ,_,
        some_DT indication_NN of_IN durability_NN of_IN viral_JJ suppression_NN might_MD be_VB
        gathered_VBN from_IN these_DT data_NNS ,_, although_IN the_DT number_NN of_IN patients_NNS
        evaluated_VBN in_IN this_DT study_NN phase_NN was_VBD small_JJ ._. The_DT durability_NN of_IN
        virologic_JJ response_NN to_TO APV_NNP 600_CD /_NN RTV_NNP was_VBD also_RB suggested_VBN in_IN an_DT
        earlier_JJR study_NN by_IN Katlama_NNP et_CC al_NN [_NN 21_CD ]_NN ._.
        The_DT increase_NN in_IN CD_NNP 4_CD +_NN cells_NNS observed_VBD at_IN 24_CD weeks_NNS in_IN the_DT
        APV_NNP 600_CD /_NN RTV_NNP BID_NNP arm_NN was_VBD not_RB different_JJ from_IN that_DT in_IN the_DT
        APV_NNP 1200_CD arm_NN ._. It_PRP was_VBD lower_JJR in_IN magnitude_NN than_IN the_DT CD_NNP 4_CD +_NN cell_NN
        count_NN increases_NNS reported_VBD for_IN APV_NNP 600_CD /_NN RTV_NNP arm_NN at_IN 24_CD weeks_NNS in_IN
        antiretroviral-experienced_JJ patients_NNS in_IN ESS_NNP 40006_CD [_NN 20_CD ]_NN ,_,
        and_CC similar_JJ to_TO that_DT reported_VBD in_IN heavily_RB pre-treated_JJ
        patients_NNS by_IN Katlama_NNP et_CC al_NN [_NN 21_CD ]_NN in_IN a_DT patient_NN population_NN
        with_IN comparable_JJ baseline_NN disease_NN characteristics_NNS (_( median_JJ
        HIV-_NNP 1_CD RNA_NNP of_IN 4_CD ._. 5_CD log_VB 
        10_CD /_NN mL_NN and_CC CD_NNP 4_CD +_NN count_NN of_IN 227_CD cells_NNS /_NN mm_NN
        3_LS )_) ._.
        The_DT safety_NN profile_NN of_IN the_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN was_VBD similar_JJ
        to_TO that_DT of_IN the_DT APV_NNP 1200_CD regimen_NN with_IN respect_NN to_TO the_DT main_JJ
        adverse_JJ events_NNS ,_, which_WDT were_VBD gastrointestinal_NN (_( GI_NNP )_) in_IN nature_NN
        in_IN both_DT treatment_NN arms_NNS ._. GI_NNP adverse_JJ events_NNS reported_VBD in_IN the_DT
        APV_NNP 600_CD /_NN RTV_NNP arm_NN were_VBD possibly_RB due_JJ to_TO the_DT addition_NN of_IN RTV_NNP to_TO
        the_DT regimen_NN ,_, or_CC because_IN the_DT reduction_NN in_IN pill_NN burden_NN and_CC ,_,
        hence_RB ,_, in_IN excipients_NNS was_VBD not_RB great_JJ enough_RB to_TO improve_VB GI_NNP
        tolerance_NN ._. The_DT higher_JJR incidence_NN of_IN oral_JJ /_NN perioral_NN
        paresthesia_NN in_IN the_DT APV_NNP 1200_CD treatment_NN arm_NN was_VBD most_RBS likely_JJ
        due_NN to_TO the_DT higher_JJR APV_NNP C_NNP 
        max_NN that_WDT occurs_VBZ following_VBG APV_NNP 1200_CD dosing_VBG
        compared_VBN with_IN APV_NNP 600_CD /_NN RTV_NNP BID_NNP dosing_VBG [_NN 17_CD ]_NN ._. Although_IN the_DT
        incidence_NN of_IN headache_NN has_VBZ been_VBN shown_VBN to_TO increase_VB with_IN
        higher_JJR APV_NNP C_NNP 
        max_NN values_NNS [_NN 18_CD ]_NN ,_, the_DT incidence_NN of_IN
        this_DT adverse_JJ event_NN did_VBD not_RB differ_VB between_IN treatment_NN arms_NNS in_IN
        this_DT study_NN ._. The_DT higher_JJR incidence_NN of_IN hypertriglyceridemia_NN in_IN
        the_DT APV_NNP 600_CD /_NN RTV_NNP arm_NN was_VBD probably_RB due_JJ to_TO RTV_NNP ,_, because_IN this_DT PI_NNP
        has_VBZ been_VBN reported_VBN to_TO cause_VB elevations_NNS in_IN serum_NN
        triglycerides_NNS [_NN 22_CD ]_NN ._. Other_JJ studies_NNS of_IN RTV-boosted_NNP APV_NNP
        regimens_NNS have_VBP also_RB reported_VBN that_DT triglyceride_NN elevation_NN is_VBZ
        usually_RB grade_NN 1_CD or_CC 2_CD in_IN magnitude_NN ,_, and_CC ,_, as_IN in_IN the_DT present_JJ
        study_NN ,_, seldom_RB necessitates_NNS treatment_NN discontinuation_NN or_CC the_DT
        addition_NN of_IN antihyperlipidemic_JJ drugs_NNS to_TO the_DT patient_NN 's_POS
        treatment_NN plan_NN [_NN 10_CD 19_CD ]_NN ._.
        This_DT study_NN evaluated_VBD a_DT patient_NN population_NN that_WDT was_VBD
        ethnically_RB diverse_JJ ,_, with_IN just_RB over_IN half_NN of_IN the_DT patients_NNS
        being_VBG either_CC African_NNP American_NNP or_CC Hispanic_JJ ._. The_DT inclusion_NN of_IN
        a_DT large_JJ proportion_NN of_IN African_NNP American_NNP and_CC Hispanic_JJ
        patients_NNS was_VBD deemed_VBN important_JJ because_IN these_DT are_VBP the_DT
        populations_NNS in_IN whom_WP the_DT HIV_NNP epidemic_NN is_VBZ increasing_VBG the_DT most_JJS
        [_NN 23_CD ]_NN ._. Earlier_JJR clinical_JJ trials_NNS have_VBP tended_VBN to_TO
        underrepresent_NN these_DT populations_NNS [_NN 24_CD ]_NN ._.
        One_CD limitation_NN of_IN our_PRP$ study_NN was_VBD that_IN no_DT pharmacokinetic_JJ
        analyses_NNS were_VBD performed_VBN to_TO validate_NN whether_IN the_DT RTV_NNP dosage_NN
        regimen_NN co-administered_JJ with_IN APV_NNP 600_CD was_VBD effectively_RB
        boosting_VBG plasma_NN APV_NNP exposure_NN or_CC C_NNP 
        min_NN levels_NNS ._. However_RB ,_, ESS_NNP 40006_CD ,_, which_WDT
        also_RB evaluated_VBD the_DT APV_NNP 600_CD /_NN RTV_NNP regimen_NN over_IN a_DT 24_CD -_: week_NN
        period_NN ,_, did_VBD conduct_NN a_DT pharmacokinetic_JJ evaluation_NN showing_VBG
        steady-state_JJ serum_NN APV_NNP C_NNP 
        min_NN values_NNS of_IN 2_CD ._. 49_CD μg_NN /_NN mL_NN (_( i_NNP ._. e_SYM ._. ,_, over_IN
        8_CD -_: fold_VB higher_JJR than_IN that_DT usually_RB achieved_VBN after_IN the_DT APV_NNP 1200_CD
        regimen_NN )_) ._. Thus_RB ,_, plasma_NN APV_NNP levels_NNS well_RB above_IN the_DT IC_NNP 
        50_CD s_VBZ of_IN most_JJS HIV_NNP isolates_VBZ were_VBD most_RBS
        likely_RB achieved_VBN in_IN ESS_NNP 40011_CD ._. Higher_JJR RTV_NNP doses_NNS of_IN 200_CD mg_NN BID_NNP
        and_CC 400_CD mg_NN BID_NNP co-administered_JJ with_IN APV_NNP 600_CD have_VBP resulted_VBN in_IN
        no_DT greater_JJR virologic_JJ suppression_NN than_IN 100_CD mg_NN BID_NNP [_NN 25_CD ]_NN ,_,
        and_CC raising_VBG the_DT dose_NN of_IN APV_NNP from_IN 600_CD mg_NN BID_NNP to_TO 900_CD mg_NN BID_NNP
        does_VBZ not_RB improve_VB efficacy_NN either_CC ,_, although_IN it_PRP may_MD increase_VB
        the_DT incidence_NN of_IN adverse_JJ events_NNS [_NN 20_CD ]_NN ._.
        In_IN conclusion_NN ,_, APV_NNP 600_CD /_NN RTV_NNP BID_NNP was_VBD similar_JJ to_TO or_CC better_JJR
        than_IN APV_NNP 1200_CD BID_NNP based_VBN on_IN virologic_JJ results_NNS using_VBG the_DT
        200_CD -_: copies_NNS /_NN mL_NN HIV-_NNP 1_CD RNA_NNP endpoint_NN ._. Of_IN note_NN ,_, a_DT significantly_RB
        greater_JJR proportion_NN of_IN patients_NNS in_IN the_DT APV_NNP 600_CD /_NN RTV_NNP treatment_NN
        arm_NN achieved_VBD HIV-_NNP 1_CD RNA_NNP <_NN 50_CD copies_NNS /_NN mL_NN at_IN week_NN 24_CD ,_, which_WDT
        was_VBD a_DT secondary_JJ endpoint_NN ._. Other_JJ beneficial_JJ features_NNS of_IN the_DT
        APV_NNP 600_CD /_NN RTV_NNP regimen_NN ,_, such_JJ as_IN improved_VBN dosing_VBG convenience_NN and_CC
        reduced_VBN pill_NN burden_NN ,_, need_VBP to_TO be_VB factored_JJ into_IN decision_NN
        making_VBG when_WRB APV_NNP 600_CD /_NN RTV_NNP is_VBZ being_VBG considered_VBN by_IN clinicians_NNS as_IN
        a_DT therapeutic_JJ option_NN for_IN the_DT treatment_NN of_IN either_DT
        antiretroviral-naïve_JJ or_CC -_: experienced_VBN patients_NNS with_IN HIV_NNP
        infection_NN ._.
      
    
  
